MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism

Peroxisome proliferator-activated receptor (PPAR)-α/γ dual agonists have been developed to treat metabolic diseases; however, most of them exhibit side effects such as body weight gain and oedema. Therefore, we developed a novel PPARα/γ dual agonist that modulates glucose and lipid metabolism withou...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seok-Ho, Hong, Shin Hee, Park, Young-Joon, Sung, Jong-Hyuk, Suh, Wonhee, Lee, Kyeong Won, Jung, Kiwon, Lim, Changjin, Kim, Jin-Hee, Kim, Hyoungsu, Park, Kyong Soo, Park, Sang Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367362/
https://www.ncbi.nlm.nih.gov/pubmed/30733541
http://dx.doi.org/10.1038/s41598-018-38281-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367362/
https://www.ncbi.nlm.nih.gov/pubmed/30733541
http://dx.doi.org/10.1038/s41598-018-38281-0

Ejemplares similares